There are limited to no data regarding the use of immune checkpoint inhibitors (ICIs) in patients who have preexisting organ dysfunction because these patients are frequently excluded from clinical trials . The authorsâ objective was to evaluate the effects of ICIs on patients with chronic kidney disease (CKD), cirrhosis, COPD, and congestive heart failure (CHF) In all four cohorts, there were no statistically significant differences in patient characteristics, treatment characteristics or outcomes, such as the number of hospitalizations and PFS, among those who experienced IrAEs .